Interaction between inulin supplementation and cyclophosphamide therapy in patients with breast cancer

Phase 2

Completed

• Conditions: Breast cancer; Cachexy; Chemotherapy toxicity; Cancer - Breast

• Registration Number: ACTRN12616001532493
• Lead Sponsor: niversidad Autonoma del Estado de Mexico- Facultad de Medicina

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-11-07
• Last Update Posted: 3 February 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Patients with clinical diagnosis of breast cancer, with score 0 according to the scale Eastern Cooperative Oncology Group (ECOG) .
Patients who agree to participate and provide the required information.
Patients with chemotherapy scheme with cyclophosphamide alone or in combination with methotrexate, 5-fluorouracil and doxorubicin.

Exclusion Criteria

Patients with an ECOG score greater than or equal to 1.
Patients who do not sign informed consent.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> The change in GSTP1 mRNA expression in lymphocytes will be analyzed by qPCR.[Measures will be perfomed previuosly (day 0) and after inulin supplementation (21 days).<br> ]<br> ;<br> The change in GSTM1 mRNA expression in lymphocytes will be analyzed by qPCR.[Measures will be perfomed previuosly (day 0) and after inulin supplementation (21 days).<br> ]<br> ;<br> The change in GSTT1 mRNA expression in lymphocytes will be analyzed by qPCR.[Measures will be perfomed previuosly (day 0) and after inulin supplementation (21 days).<br> ]<br>